CLAIMS

1. A combination of :

component A : one or more omega-carboxyaryl-substituted diphenyl urea compounds of general formula (I) :

A - D - B

(I)

wherein

D is -NH-C(O)-NH-,

A is a substituted moiety of up to 40 carbon atoms of the formula: -L-(M-L^1)$_q$, where L is a 5 or 6 membered cyclic structure bound directly to D, L^1 comprises a substituted cyclic moiety having at least 5 members, M is a bridging group having at least one atom, q is an integer of from 1-3; and each cyclic structure of L and L^1 contains 0-4 members of the group consisting of nitrogen, oxygen and sulfur, and

B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur,

wherein L^1 is substituted by at least one substituent selected from the group consisting of -SO_2R_x, -$C(O)R_x$ and -$C(NR_y)$ R_z,

R_y is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally halosubstituted, up to per halo,

R_z is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24

carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;

R_x is R_z or NR_aR_b where R_a and R_b are

a) independently hydrogen,

a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen, or

$-OSi(R_f)_3$ where R_f is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or

b) R_a and R_b together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O substituted by halogen, hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or

c) one of R_a or R_b is -C(O)-, a C_1-C_5 divalent alkylene group or a substituted C_1-C_5 divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C_1-C_5 divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;


where B is substituted, L is substituted or L^1 is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and Wn, where n is 0-3;

wherein each W is independently selected from the group consisting of -CN, $-CO_2R^7$, $-C(O)NR^7R^7$, $-C(O)-R^7$, $-NO_2$, $-OR^7$, $-SR^7$, $-NR^7R^7$, $-NR^7C(O)OR^7$, $-NR^7C(O)R^7$, -Q-Ar, and carbon based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents independently selected from the group consisting of -CN, $-CO_2R^7$, $-C(O)R^7$, $-C(O)NR^7R^7$, $-OR^7$, $-SR^7$, $-NR^7R^7$, $-NO_2$, $-NR^7C(O)R^7$, $-NR^7C(O)OR^7$ and halogen up to per-halo; with each R^7 independently selected from H or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen,

wherein Q is -O-, -S-, $-N(R^7)-$, $-(CH_2)_m-$, -C(O)-, -CH(OH)-, $-(CH_2)_mO-$, $-(CH_2)_mS-$, $-(CH_2)_mN(R^7)-$, $-O(CH_2)_m-$ CHX^a-, $-CX^a_2-$, $-S-(CH_2)_m-$ and $-N(R^7)(CH_2)_m-$, where m= 1-3, and X^a is halogen; and

Ar is a 5- or 6-member aromatic structure containing 0-2 members selected from the group consisting of nitrogen, oxygen and sulfur, which is optionally substituted by halogen, up to per-halo, and optionally substituted by Z_{n1}, wherein n1 is 0 to 3 and each Z is independently selected from the group consisting of -CN, $-CO_2R^7$, $-C(O)R^7$, $-C(O)NR^7R^7$, $-NO_2$, $-OR^7$, $-SR^7$ $-NR^7R^7$, $-NR^7C(O)OR^7$, $-NR^7C(O)R^7$, and a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents selected from the group consisting of -CN, $-CO_2R^7$, $-COR^7$, $-C(O)NR^7R^7$, $-OR^7$, $-SR^7$, $-NO_2$, $-NR^7R^7$, $-NR^7C(O)R^7$, and $-NR^7C(O)OR^7$, with R^7 as defined above,


with the proviso that said compound of general formula (I) is not :



or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof ; optionally in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially ;

and

component B : one or more N-(2-arylamino) aryl sulfonamide compounds of general formula (II) :



(B)

where G is R_{1a}, R_{1b}, R_{1c}, R_{1d}, R_{1e}, Ar_1, Ar_2 or Ar_3; R° is H, halogen, C_1-C_6 alkyl, C_1-C_4 alkoxy, C_3-C_6 cycloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, said alkyl, cycloalkyl, alkenyl, and alkynyl groups optionally substituted with 1-3 substituents selected independently from halogen, OH, CN, cyanomethyl, nitro, phenyl, and trifluoromethyl, and said C_1-C_6 alkyl and C_1-C_4 alkoxy groups also optionally substituted with OCH_3 or OCH_2CH_3; X is F, Cl or methyl; Y is I, Br, Cl, CF_3, C_1-C_3 alkyl, C_2-C_3 alkenyl, C_2-C_3 alkynyl, cyclopropyl, phenyl, pyridyl, pyrazolyl, OMe, OEt, or SMe, where all said methyl, ethyl, C_1-C_3 alkyl, and cyclopropyl groups of X and Y are optionally substituted with OH, all said

phenyl, pyridyl, pyrazolyl groups of Y are optionally substituted with halogen, acetyl, methyl, and trifluoromethyl, and all said methyl groups of X and Y are optionally substituted with one, two, or three F atoms; and Z is H or F,


where R_{1a} is methyl, optionally substituted with 1-3 fluorine atoms or 1-3 chlorine atoms, or with OH, cyclopropoxy, or C_1- C_4 alkoxy, where the C_1- C_4 alkyl moieties of said C_1- C_4 alkoxy groups are optionally substituted with one hydroxy or methoxy group, and where all C_2- C_4 alkyl groups within said C_1- C_4 alkoxy are optionally further substituted with a second OH group;

R_{1b} is $CH(CH_3)$-C_{1-3} alkyl or C_3-C_6 cycloalkyl, said methyl, alkyl, and cycloalkyl groups optionally substituted with 1-3 substituents selected independently from F, Cl, Br, I, OH, C_1- C_4 alkoxy, and CN;

R_{1c} is $(CH_2)_nO_mR'$, where m is 0 or 1; where, when m is 1, n is 2 or 3, and when m is 0, n is 1 or 2; and where R' is C_1-C_6 alkyl, optionally substituted with 1-3 substituents selected independently from F, Cl, OH, OCH_3, OCH_2CH_3, and C_3-C_6 cycloalkyl;


R_{1d} is C(A)(A')(B)- where B, A, and A' are, independently, H or C_{1-4} alkyl, optionally substituted with one or two OH groups or halogen atoms, or A and A', together with the carbon atom to which they are attached, form a 3- to 6-member saturated ring, said ring optionally containing one or two heteroatoms selected, independently, from O, N, and S and optionally substituted with one or two groups selected independently from methyl, ethyl, and halo;

R_{1e} is benzyl or 2-phenyl ethyl, in which the phenyl group is optionally substituted




where q is 1 or 2, R_2, R_3 and R_4 are, independently, H, F, Cl, Br, CH_3, CH_2F, CHF_2, CF_3, OCH_3, OCH_2F, $OCHF_2$, OCF_3, ethyl, *n*-propyl, isopropyl, cyclopropyl, isobutyl, *sec*-butyl, *tert*-butyl, and methylsulfonyl, and R_4 may also be nitro, acetamido, amidinyl, cyano, carbamoyl, methylcarbamoyl, dimethylcarbamoyl, 1,3,4-oxadiazol-2-yl, 5-methyl-1,3,4-oxadiazolyl, 1,3,4-thiadiazolyl, 5-methyl-1,3,4-thiadiazol-*1H*-tetrazolyl, N-morpholinyl carbonylamino, N-morpholinylsulfonyl, and N-pyrrolidinylcarbonylamino; R_5 and R_6 are, independently, H, F, Cl, or methyl;

Ar_1 is



where U and V are, independently, N, CR_2 or CR_3; R_2, R_3 and R_4 are, independently, H, F, Cl, Br, CH_3, CH_2F, CHF_2, CF_3, OCH_3, OCH_2F, $OCHF_2$, OCF_3, ethyl, *n*-propyl, isopropyl, cyclopropyl, isobutyl, *sec*-butyl, *tert*-butyl, and methylsulfonyl, and R_4 may also be nitro, acetamido, amidinyl, cyano, carbamoyl, methylcarbamoyl, dimethylcarbamoyl, 1,3,4-oxadiazol-2-yl, 5-methyl-1,3,4-oxadiazol, 1,3,4-thiadiazol, 5-methyl-1,3,4-thiadiazol 1H-tetrazolyl, N-morpholinylcarbonylamino, N-morpholinylsulfonyl and N-pyrrolidinylcarbonylamino; R_5 and R_6 are, independently, H, F, Cl or methyl;

Ar_2 is




Ar_2

where the dashed line represents a double bond which may be located formally either between V and the carbon between U and V, or between U and the

carbon between U and V; where U is -S-, -O- or -N = and where, when U is -O- or -S-, V is -CH=, -CCl= or -N =; and when U is -N =, V CH=, or -NCH_3-; R_7 and R_8 are, independently, H, methoxycarbonyl, methylcarbamoyl, acetamido, acetyl, methyl, ethyl, trifluoromethyl, or halogen.

Ar_3 is



Ar_3

where U is -NH-, -NCH_3- or -O-; and R_7 and R_8 are, independently, H, F, Cl, or methyl ;

or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof ;


optionally in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially ;




and, optionally,


component C : one or more further pharmaceutical agents.





2. The combination according to claim 1, wherein :


said component A is one or more omega-carboxyaryl-substituted diphenyl urea compounds of general formula (I) according to claim 1, which is selected from the list consisting of :
























Example entry	R
1	
2	
3	















Example entry	R
4	
5	
6	
7	








Example entry	R
8	
9	
10	
11	
12	
13	
14	
15	
16	












17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	












29	
30	
31	
32	
33	
34	
35	
36	
37	










38	
39	
40	












Example entry	R
41	
43	
44	
45	










46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	


57	
58	
59	
60	
61	
62	
63	
64	
65	
66	
67	


68	
69	
70	
71	
72	
73	
74	
75	
76	







77	
78	
79	
80	
81	
82	
83	
84	






Example entry	R
85	
86	
87	
88	
89	
90	
91	
92	
93	

94	




Example entry	R
95	
96	
97	
98	
99	
100	

Example entry	Structure

101	
102	
103	

or



or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof,

optionally in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially.

3. The combination according to claim 1 or 2, wherein :

said component B is one or more N-(2-arylamino) aryl sulfonamide compounds of general formula (II) according to claim 1, which is selected from the list consisting of :

Example 1 : N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-methanesulfonamide:

Example 2 : N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)cyclopropanesulfonamide:

Example 3 : N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)propane-2-sulfonamide:

Example 4 : N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)butane-1-sulfonamide:

Example 5 : N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-2,2,2-trifluoro ethane sulfonamide:

Example 6 : N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)butane-2-sulfonamide:

Example 7 : N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-N-methyl cyclopropane sulfonamide:

Example 8 : 1-Chloro-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl) methane sulfonamide:

Example 9 : N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-2-methylpropane-2-sulfonamide:

Example 10 : N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)cyclopentanesulfonamide:

Example 11 : N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)cyclohexanesulfonamide:

Example 12 : N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-1-methylcyclopropane-1-sulfonamide:

Example 13 : N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-1-(2,3-dihydroxypropyl) cyclopropane-1-sulfonamide:

Example 14 : (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide:

Example 15 : (R)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide:

Example 16 : N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-1-(2-hydroxyethyl)cyclopropane-1-sulfonamide:

Example 17 : N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-3-hydroxypropane-1-sulfonamide:

Example 18 : N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-2-methyl-5-(trifluoromethyl)furan-3-sulfonamide:

Example 19 : N-(5-(N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)sulfamoyl)- methylthiazol-2-yl)acetamide:

Example 20 : 5-(5-Chloro-1,2,4-thiadiazol-3-yl)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino) phenyl) thiophene-2-sulfonamide:

Example 21 : N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-3,5dimethylisoxazole-4-sulfonamide:

Example 22 : 5-Chloro-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-1,3-dimethyl-1H-pyrazole-4-sulfonamide:

Example 23 : N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-2,5-dimethylfuran-3-sulfonamide:

Example 24 : N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-1-methyl-3-(trifluoromethyl)-1H-pyrazole-4-sulfonamide:

Example 25 : N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-2,4-dimethylthiazole-5-sulfonamide:

Example 26 : N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-1,2-dimethyl-1H-imidazole-4-sulfonamide:

Example 27 : N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)thiophene-3-sulfonamide:

Example 28 : N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)furan-2-sulfonamide:

Example 29 : N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-5-methylthiophene-2-sulfonamide:

Example 30 : 5-Chloro-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)thiophene-2-sulfonamide:

Example 31 : 5-Bromo-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)thiophene-2-sulfonamide:

Example 32 : 4-Bromo-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)thiophene-3-sulfonamide:

Example 33 : 4-Bromo-5-chloro-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)thiophene-2-sulfonamide:

Example 34 : 3-Bromo-5-chloro-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)thiophene-2-sulfonamide:

Example 35 : N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-2,5-dimethylthiophene-3-sulfonamide:

Example 36 : 2,5-Dichloro-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)thiophene-3-sulfonamide:

Example 37 : Methyl 3-(N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)sulfamoyl)thiophene-2-carboxylate:

Example 38 : Methyl 5-(N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)sulfamoyl)-1-methyl-1H-pyrrole-2-carboxylate:

Example 39 : N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-5-methylisoxazole-4-sulfonamide:

Example 40 : 3-Chloro-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)propane-1-sulfonamide:

Example 41 : N-(2-(4-chloro-2-fluorophenylamino)-3,4-difluorophenyl)cyclopropanesulfonamide:

Example 42 : N-(3,4-difluoro-2-(4-iodo-2-methylphenylamino)phenyl)cyclopropanesulfonamide:

Example 43 : N-(2-(4-tert-butyl-2-chlorophenylamino)-3,4-difluorophenyl)cyclopropanesulfonamide:

Example 44 : N-(2-(2,4-dichlorophenylamino)-3,4-difluorophenyl)cyclopropanesulfonamide:

Example 45 : 3-Chloro-N-(3,4-difluoro-2-(2-fluoro-4-trifluoromethyl)phenylamino)phenyl)propane-1-sulfonamide:

Example 46 : N-(3,4-difluoro-2-(2-chloro-4-trifluoromethyl)phenylamino)methanesulfonamide:

Example 47 : 3-Chloro-N-(3,4-difluoro-2-(2-chloro-4-trifluoromethyl) phenylamino)phenyl)propane-1-sulfonamide:

Example 48 : 3-Chloro-N-(3,4-difluoro-2-(2-bromo-4-trifluoromethyl) phenylamino)phenyl)propane-1-sulfonamide:

Example 49 : Cyclopropanesulfonic acid (3,4,6-trifluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl)-amide:

Example 50 : N-(3,4-difluoro-2-(4-fluoro-2-iodophenylamino)-6-ethoxyphenyl) cyclopropane sulfonamide:

Example 51 : Methylsulfonic acid (3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-6-methoxy-phenyl)-amide:

Example 52 : 1-(2,3-Dihydroxy-propyl)-cyclopropanesulfonic acid [3,4,6-trifluoro-2-(4-fluoro-2-iodo-phenylamino)-phenyl]-amide:

Example 53 : (S)-1-(2,3-dihydroxypropyl)-N-(3,4,6-trifluoro-2-(2-fluoro-4-iodophenylamino) phenyl)cyclopropane-1-sulfonamide:

Example 54 : (R)-1-(2,3-dihydroxypropyl)-N-(3,4,6-trifluoro-2-(2-fluoro-4-iodophenylamino) phenyl)cyclopropane-1-sulfonamide:

Example 55 : N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-1-(2,3-dihydroxypropyl) cyclopropane-1-sulfonamide:

Example 56 : (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide:

Example 57 : (R)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide:

Example 58 : 1-(2-hydroxyethyl)-N-(3,4,6-trifluoro-2-(2-fluoro-4-iodophenylamino)phenyl) cyclopropane-1-sulfonamide:

Example 59 : N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2-hydroxyethyl)cyclopropane-1-sulfonamide:

Example 60 : N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(3-hydroxy-2-(hydroxymethyl)propyl)cyclopropane-1-sulfonamide:

Example 61 : N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl) cyclobutane sulfonamide:

Example 62 : N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methylphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide:

Example 63 : 1-(2,3-Dihydroxypropyl)-N-(6-ethyl-3,4-difluoro-2-(2-fluoro-4-iodophenylamino) phenyl) cyclopropane-1-sulfonamide:

Example 64 : N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-(2-methoxyethoxy)phenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide:

Example 65 : 2, 4-dichloro-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl) benzene sulfonamide:

Example 66 : 2-chloro-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-4-(trifluoromethyl) benzenesulfonamide:

Example 67 : N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-2-(trifluoromethoxy) benzene sulfonamide:

Example 68 : 4-(N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)sulfamoyl)benzoic acid:


Example 69 : N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)benzenesulfonamide:

Example 70 : N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-2-fluorobenzene sulfonamide:

Example 71 : N-(3,4-difluoro-2-(2-fluoro-4-methylphenylamino)phenyl)cyclopropanesulfonamide ;


or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof ; optionally in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially.

4. The combination according to any one of claims 1 to 3, wherein said component A is :



5. The combination according to any one of claims 1 to 4, wherein said component B is (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide.

6. The combination according to any one of claims 1 to 5, wherein said component A is :



and
component B is :

(S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide.

7. Use of a combination according to any one of claims 1 to 6 for the preparation of a medicament for the treatment or prophylaxis of a cancer, particularly hepatocyte carcinoma, lung cancer, in particular non-small cell lung carcinoma, colorectal cancer, melanoma, pancreatic cancer or breast cancer.

8. A kit comprising a combination of :


component A : one or more omega-carboxyaryl-substituted diphenyl urea compounds of general formula (I), or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof, according to any one of claims 1 to 6 ;

component B : one or more N-(2-arylamino) aryl sulfonamide compounds of general formula (II), or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof, according to any one of claims 1 to 6 ; and, optionally,

component C : one or more further pharmaceutical agents, according to any one of claims 1 to 6 ;

in which optionally both or either of said components A and B are in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially.

9. The kit according to claim 8, wherein said component A is :



and


component B is :

(S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide.

CLAIMS

1. A combination of :

component A :




or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof ;
optionally in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially ;
and

component B :

(S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof ;
optionally in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially ;
and, optionally,

component C : one or more further pharmaceutical agents.

2. The combination according to claim 1, wherein said component A is :



and

component B is :


(S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide.

3. Use of a combination according to claim 1 or 2 for the preparation of a medicament for the treatment or prophylaxis of a cancer, particularly hepatocyte

carcinoma, lung cancer, in particular non-small cell lung carcinoma, colorectal cancer, melanoma, pancreatic cancer or breast cancer.

4. A kit comprising a combination of :

component A :



, or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof ;

component B :


(S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide, or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof ;

and, optionally,

component C : one or more further pharmaceutical agents, according to claim 1 or 2 ;

in which optionally both or either of said components A and B are in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially.

5. The kit according to claim 4, wherein said component A is :



and

component B is :

(S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide.